Stock Report

Download full stock data and analysis for free Last Updated: 29-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Alivus Life Sciences Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: GLS | BSE: 543322

₹1,350.20

up-down-arrow ₹-8.00 (-0.59%)

As on 28-Aug-2026IST

Market cap

info icon

₹16,589 Cr

Revenue (TTM)

info icon

₹2,590 Cr

P/E Ratio

info icon

27.5

P/B Ratio

info icon

4.8

Div. Yield

info icon

0.4 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -7.07 6.41 7.93 4.81 5.17
EBIT -1.65 23.11 19.88 5.58 5.57
Net Profit -1.59 31.71 25.58 8.03 10.88
EPS -1.59 31.59 21.50 6.84 17.28
Book Value -- -- 18.24 15.91 31.15
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 27.1827.3129.2528.2926.06
Net Margin info 20.7320.6222.6321.6120.06
Return on equity info 19.5022.1419.6118.4118.94
Return on Capital info 26.1430.14--24.6125.50
Return on Assets info 13.8614.7116.3114.2713.34
Debt to Equity (x) info ----0.000.000.00

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
--
24.61
25.50
28.31
30.01
Peer Median
--
15.48
16.46
15.49
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

19.61

Higher than Peers by 9.67

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
19.61
18.41
18.94
21.15
22.33
Peer Median
9.94
12.68
13.87
14.72
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

16.31

Higher than Peers by 9.05

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
16.31
14.27
13.34
13.96
15.43
Peer Median
7.26
7.69
8.04
7.19
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

29.25

Higher than Peers by 19.71

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
29.25
28.29
26.06
27.19
27.77
Peer Median
9.55
15.68
10.05
10.28
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

22.63

Higher than Peers by 14.00

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
22.63
21.61
20.06
20.52
21.32
Peer Median
8.64
11.16
9.11
6.78
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
--
24.81
22.79
22.90
23.43
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

7.93

Higher than Peers by 1.69

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
7.93
6.91
4.54
5.64
1.79
Peer Median
6.24
15.05
7.17
10.56
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

19.88

Higher than Peers by 19.94

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
19.88
16.07
0.19
3.43
3.81
Peer Median
-0.06
19.88
12.05
6.17
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

25.58

Higher than Peers by 18.00

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
25.58
16.24
3.13
0.84
11.52
Peer Median
7.58
19.11
22.15
27.97
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

21.50

Higher than Peers by 19.32

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
21.50
16.05
3.12
0.84
11.52
Peer Median
2.18
23.11
8.80
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
--
18.43
20.94
8.90
3.94
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
--
--
--
--
--
Peer Median
0.02
0.12
0.03
0.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

5.21

Higher than Peers by 2.77

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
5.21
4.14
4.97
4.37
2.33
Peer Median
2.45
2.48
2.20
1.93
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.85

Higher than Peers by 2.14

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
3.85
3.12
3.53
2.85
1.74
Peer Median
1.72
1.82
1.72
1.59
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

148.49

Higher than Peers by 138.77

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
148.49
140.86
271.97
409.34
1,150.19
Peer Median
9.71
13.67
12.28
12.45
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

41.42

Higher than Peers by 14.51

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
41.42
42.05
40.63
33.52
37.33
Peer Median
26.91
30.65
26.23
23.97
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.70

Higher than Peers by 0.03

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
0.70
0.65
0.66
0.68
0.72
Peer Median
0.67
0.70
0.74
0.88
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
--
144.58
132.12
125.30
124.34
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
--
96.67
102.08
101.28
94.11
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
--
135.45
133.54
149.95
136.29
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
--
105.80
100.66
76.63
82.16
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

27.51

Lower than Peers by 27.56

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
27.51
21.18
27.24
20.17
10.28
Peer Median
55.07
55.07
39.17
40.74
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

4.76

Higher than Peers by 0.28

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
4.76
3.60
4.71
4.09
2.25
Peer Median
4.48
4.76
3.61
3.87
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

0.37

Higher than Peers by 0.22

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
0.37
0.51
0.46
2.90
5.36
Peer Median
0.15
0.15
0.19
0.20
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

18.22

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
18.22
13.94
18.35
13.40
6.69
Peer Median
--
39.78
28.79
25.41
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

16,589

Higher than Peers by 10,770

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alivus Life Sciences
16,589
11,957
13,229
9,499
4,798
Peer Median
5,820
5,820
3,944
2,959
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...